Our modern world needs a modern Food and Drug Administration (FDA). As PDUFA VIII offers a historic opportunity to make the drug review program faster, more consistent, and more transparent, here are a few suggestions we heard from our network of experts.

“You shouldn’t have to fight your cancer and your insurance company’s co-payments."

Cambridge is home to the world's most innovative biotech companies. Resident Neil Kairen explains the importance of this industry and suggests explanations for why so many misunderstand its value.

Here are five policies President Biden should include in his State of the Union address on Thursday.

Researchers in Pennsylvania are working on a cure for Parkinson’s. Price controls threaten their progress.

A company in Virginia is working on a vaccine to protect babies from rotavirus and norovirus.

NPLB noted that including factors, such as diminishing returns and dynamic pricing, helps assess medication value better than traditional CEA.

Rubin speaks about how drugs aren’t being properly valued.

No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value

Read what one oncology executive discovered when he surveyed the biotech community.

Letter calls nine-year price-setting threshold a threat to entire industry

Governments around the world have withheld access to life-changing medications for people with cystic fibrosis (CF) for years in the name of being hawkish on drug pricing.